Verneuil Vanina De Sells 1,403 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 1,403 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $7.20, for a total transaction of $10,101.60. Following the completion of the sale, the executive vice president now directly owns 63,717 shares of the company’s stock, valued at $458,762.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Verneuil Vanina De also recently made the following trade(s):

• On Tuesday, November 5th, Verneuil Vanina De sold 2,347 shares of Vir Biotechnology stock. The stock was sold at an average price of $9.47, for a total transaction of $22,226.09.

Vir Biotechnology Trading Up 5.5 %

Shares of Vir Biotechnology stock opened at $10.17 on Thursday. Vir Biotechnology, Inc. has a 12-month low of $7.12 and a 12-month high of $13.09. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -2.59 and a beta of 0.46. The firm’s 50 day simple moving average is $7.80 and its two-hundred day simple moving average is $8.90.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The company had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. During the same quarter in the previous year, the company posted ($1.22) EPS. The company’s revenue for the quarter was down 9.8% compared to the same quarter last year. On average, sell-side analysts predict that Vir Biotechnology, Inc. will post -3.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on VIR. Barclays lowered their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Monday. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a research note on Friday, November 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research note on Monday. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $36.40.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Vir Biotechnology by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 12,375,355 shares of the company’s stock valued at $125,362,000 after purchasing an additional 78,216 shares in the last quarter. Millennium Management LLC increased its stake in shares of Vir Biotechnology by 94.6% in the second quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock worth $11,108,000 after acquiring an additional 606,804 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Vir Biotechnology by 0.8% in the second quarter. Bank of New York Mellon Corp now owns 813,288 shares of the company’s stock worth $7,238,000 after acquiring an additional 6,359 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Vir Biotechnology by 10.1% in the second quarter. Dimensional Fund Advisors LP now owns 637,486 shares of the company’s stock worth $5,673,000 after acquiring an additional 58,360 shares during the period. Finally, Empowered Funds LLC increased its stake in shares of Vir Biotechnology by 8.2% in the first quarter. Empowered Funds LLC now owns 458,044 shares of the company’s stock worth $4,640,000 after acquiring an additional 34,640 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).